Gene and protein domain-specific patterns of genetic variability within the G-protein coupled receptor superfamily

American Journal of PharmacoGenomics

Volumn 3, Issue 1, 2003, Pages 65-71

  Small, Kersten M ^a   Tanguay, Debra A ^b   Nandabalan, Krishnan ^b   Zhan, Ping ^b   Stephens, J Claiborne ^b   Liggett, Stephen B ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Clinical Data Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME PHOSPHORYLATION; EXON; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INTRON; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM;

ANALYSIS OF VARIANCE; GTP-BINDING PROTEINS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 0037222999     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303010-00008     Document Type: Article

References (29)

1. Rana BK, Shiina T, Insel PA. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu Rev Pharmacol Toxicol 2001; 41: 593-624
2. Muller G, Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach. Curr Med Chem 2000; 7: 861-88
3. Gershengorn MC, Osman R. Minireview: insights into G protein-coupled receptor function using molecular models. Endocrinology 2001; 142: 2-10
4. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56: 1054-70
5. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the β2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162: 75-80
6. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97: 10483-8
7. Grant JA, Danielson L, Rihoux J-P, et al. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo. Allergy 1999; 54: 700-7
8. van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol 1998; 32 Suppl. 1: S31-5
9. Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-13
10. Cravchik A, Sibley DR, Gejman PV. Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. Pharmacogenetics 1999; 9: 17-23
11. Kiel S, Bruss M, Bonisch H, et al. Pharmacological properties of the naturally occurring Phe-124-Cys variant of the human 5-HT1B receptor: changes in ligand binding, G-protein coupling and second messenger formation. Pharmacogenetics 2000; 10: 655-66
12. Bray MS, Krushkal J, Li L, et al. Positional genomic analysis identifies the β2-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 2000; 101: 2877-82
13. Liggett SB, Wagoner LE, Craft LL, et al. The 11e164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534-9
14. Wagoner LE, Craft LL, Singh B, et al. Polymorphisms of the β 2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000; 86: 834-40
15. Small KM, Seman CA, Castator A, et al. False positive non-synonymous polymorphisms of G-protein coupled receptor genes. FEBS Lett 2002; 516: 253-6
16. Stephens JC, Schneider JA, Tanguay DA, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293: 489-93
17. Grantham R. Amino acid difference formula to help explain protein evolution. Science 1974; 185: 862-4
18. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289: 739-45
19. Rothman KJ, Greenland S, editors. Modern epidemiology. Philadelphia (PA): Lippincott-Raven, 1998
20. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 1998; 25: 1032-7
21. Lee NH, Earle-Hughes J, Fraser CM. Agonist-mediated destabilization of m1 muscarinic acetylcholine receptor mRNA: elements involved in mRNA stability are localized in the 3′-untranslated region. J Biol Chem 1994; 269: 4291-8
22. Lu ZL, Saldanha JW, Hulme EC. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol Sci 2002; 23: 140-6
23. Hausdorff WP, Bouvier M, O'Dowd BF, et al. Phosphorylation sites on two domains of the β2-adrenergic receptor are involved in distinct pathways of receptor desensitization. J Biol Chem 1989; 264: 12657-65
24. Eason MG, Moreira SP, Liggett SB. Four consecutive serines in the third intracellular loop are the sites for βARK-mediated phosphorylation and desensitization of the α2A-adrenergic receptor. J Biol Chem 1995; 270: 4681-8
25. Liang M, Eason MG, Theiss CT, et al. Phosphorylation of Ser360 in the third intracellular loop of the α2A-adrenoceptor during protein kinase C-mediated desensitization. Eur J Pharmacol 2002; 437: 41-6
26. Haga K, Kameyama K, Haga T, et al. Phosphorylation of human m1 muscarinic acetylcholine receptors by G protein-coupled receptor kinase 2 and protein kinase C. J Biol Chem 1996; 271: 2776-82
27. Gilchrist A, Li A, Hamm HE. Design and use of C-terminal minigene vectors for studying role of heterotrimeric G proteins. Methods Enzymol 2002; 344: 58-69
28. Mundell SJ, Benovic JL, Kelly E. A dominant negative mutant of the G protein-coupled receptor kinase 2 selectively attenuates adenosine A2 receptor desensitization. Mol Pharmacol 1997; 51: 991-8
29. Judson R, Stephens JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 2000; 1: 1-12